Skip to content
Bored Studies
RecruitingPhase 2

A Study Evaluating TRIV-573 in Atopic Dermatitis

Triveni Bio · NCT07782333

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
90
US sites recruiting
13
Study start
September 9, 2026
Record last updated
October 28, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.

Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).

The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.

Being studied: TRIV-573; Placebo

Conditions: Atopic Dermatitis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Has Atopic Dermatitis.
  • Has moderate to severe, active and symptomatic atopic dermatitis.

Exclusion Criteria

  • Severe or uncontrolled medical conditions.
  • Use of prohibited medications within stated washout periods.

Recruiting US locations

  • Triveni Bio Site #15

    Fountain Valley, CA 92708

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #4

    Los Angeles, CA 90045

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #11

    Boca Raton, FL 33486

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #7

    Miami, FL 33126

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #3

    Miami, FL 33142

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #2

    Indianapolis, IN 46250

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #13

    Bay City, MI 48706

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #16

    Boardman, OH 44512

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #1

    Camp Hill, PA 17011

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #14

    Myrtle Beach, SC 29588

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #9

    San Antonio, TX 78213

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #6

    San Antonio, TX 78218

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

  • Triveni Bio Site #8

    Spokane, WA 99202

    Site contact: Study Director · 781-472-2230 · clinicaltrials@triveni.bio

Study contacts (from the official record)

  • Triveni Bio, Inc · +1 (781) 472-2230 · clinicaltrials@triveni.bio
All dermatology studies in California →
A Study Evaluating TRIV-573 in Atopic Dermatitis (NCT07782333) | Bored Studies